Hormonal treatment of acne in women

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 12, 2009, Pages 16-22

  Ebede, Tobechi L ^a   Arch, Emily L ^a   Berson, Diane ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; LUTEINIZING HORMONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; POTASSIUM; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE;

ACNE VULGARIS; ANDROGEN SYNTHESIS; ANOREXIA; ARTICLE; BACTERIAL COLONIZATION; BREAKTHROUGH BLEEDING; BREAST AUGMENTATION; BREAST TENDERNESS; CLINICAL TRIAL; CONFUSION; CONGENITAL ADRENAL HYPERPLASIA; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; ENDOCRINE FUNCTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEPATITIS; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERKALEMIA; IMPOTENCE; KERATINIZATION; LIBIDO; LIVER TOXICITY; MALE TYPE ALOPECIA; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY POLYCYSTIC DISEASE; OVARY TUMOR; POTASSIUM BLOOD LEVEL; PROPIONIBACTERIUM ACNES; PROSTATE CANCER; SEBUM SECRETION; SIDE EFFECT; TREATMENT DURATION; VOMITING;

EID: 77954252475     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dreno B, Poli F. Epidemiology of acne. Dermatology. 2003;206:7-10.
2. James W. Acne. N Engl J Med. 2005;352;14:1463-1472.
3. Collier C, Harper J, Cantrell W, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58:56-59.
4. Goulden V, Clark S, Cunliffe W. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997;136:66-70.
5. Thiboutot D, Gollnick H, Betolli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009; 60:S1-S50.
6. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008; 27:188-196.
7. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292(6):726-735.
8. Clarke S, Nelson A, George R, et al. Pharmacologic modulation of sebaceous gland activity: Mechanisms and clinical applications. Dermatol Clin. 2007;25:137-146.
9. Thiboutot D. Overview of acne and its treatment. Cutis. 2008;81(S1):3-7.
10. Labrie F, Luu-The V, Labrie C, et al. Intracrinology of the skin. Horm Res. 2000;54:218-229.
11. Zoubolis C, Baron J, Bohm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17:542-551.
12. Thiboutot D, Martin P, Volikos L, et al. Oxidative activity of the type 2 isozyme of 17B-Hydroxysteroid dehydrogenase (17B-HSD) predominates in human sebaceous glands. J Invest Dermatol. 1998;111:390-395.
13. Thiboutot D, Harris G, Iles V, et al. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105:209-214.
14. Thiboutot D, Knaggs H, Gilliland K, et al. Activity of type 1 5· -reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997;136:166-171.
15. Bhambri S, Del Ross J, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009;8: 615-618.
16. Rich P. Hormonal contraceptives for acne management. Cutis. 2008;81(suppl 1):13-18.
17. O'Connell K, Westhoff C. Pharmocology of hormonal contraceptives and acne. Cutis. 2008;81(suppl 1):8-12.
18. Shaw J. Acne: Effects on hormones on pathogenesis and management. Am J Clin Dermatol. 2002; 3:571-578.
19. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57-67.
20. Thiboutot D. Acne: Hormonal concepts and therapy. Clin Dermatol. 2004;22:419-428.
21. Thiboutot D. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):57-61.
22. Lucky A. Quantitative documentation of a premenstrual flare of facial acne in adult women. Arch Dermatol. 2004;140:423-424.
23. Shaw J. Spironolactone in dermatologic therapy. J Am Acad Dermatol. 1991;24:236-243.
24. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systemic Reviews. 2009; Issue 2.
25. Yemisci A, Gorgulu A, Piskin S. Effects and side effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19:163-166.
26. Walton S, Cunliffe W, Lookingbill P, et al. Lack of effect of topical spironolactone on sebum excretion. Br J Dermatol. 1986; 114:261-264.
27. Tan J. Hormonal treatment of acne: Review of current best evidence. J Cutan Med Surg. 2005; 8(suppl 4):11-15.
28. Spironolactone. http://www.drugs.com/pro/aldactone.html. Accessed on October 8, 2009.
29. Cassidenti DL, Paulson RJ, Serafini P, et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991;78:103-107.
30. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med. 2002;47:975-980.
31. Maloney M, Arbit D, Flack M, et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health. 2001;1:123-131.
32. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37:746-754.
33. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl stradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615-622.
34. Lucky AW, Koltun W, Thiboutot D, et al. A combined oral contraceptive containing 3mg drospirenone/20μg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82:143-150.
35. Maloney M, Dietze P, Watson D, et al. Treatment of acne using a 3mg drospirenone/20μg ethinyl estradiol oral contraceptive administered in a 24/4 regimen. Obstet Gynecol. 2008;112:773-781.
36. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(suppl 4):2-15.
37. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123-130.
38. Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol. 2008;58:781-786.
39. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric. 2008;11:355-363.